Advertisement

Topics

Canaccord Genuity Analysts Give Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) a $522.00 Price Target

21:19 EDT 30 Jul 2017 | Topix

The firm presently has a "buy" rating on the biopharmaceutical company's stock. Canaccord Genuity's price objective suggests a potential upside of 2.61% from the stock's current price.

Original Article: Canaccord Genuity Analysts Give Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) a $522.00 Price Target

NEXT ARTICLE

More From BioPortfolio on "Canaccord Genuity Analysts Give Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) a $522.00 Price Target"

Quick Search
Advertisement
 

Relevant Topic

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...